CLLS cellectis.com: Projected Price to Earnings

Corporate company logo of Cellectis (CLLS)

Cellectis S.A. (CLLS) is the European leader in gene modification for oncology. This price chart illustrates the dynamics of an asset whose capabilities in creating universal cells allow it to dictate favorable terms to pharma behemoths. The current P/E ratio is 0.00. The business currently relies on the clinical trial stage, meaning market pricing does not impact profits, although the value of its CAR-T patents remains extremely high.

Cellectis S.A. - CLLS Future Price to Earnings Multiple (period 07/04/2022 - 11/10/2026)

Summary analytical data breakdowns for Cellectis Biotherapeutics (CLLS)

- stock quotes and analyst forecast:
Stock Price Cellectis S.A.|CLLS - Analyst Target Range
- company stock capitalization data:
Market Valuation Cellectis SA|CLLS - Total Enterprise Value
- issuer book value statistics:
Accounting Value per Share Cellectis S.A.|CLLS - Accounting Value of Company|Market Capitalization to Book Value Ratio cellectis.com|CLLS - Cumulative Company Assets
- debt level and financial liquidity data:
Total Debt to Capital Cellectis S.A.|CLLS - Long-Term Liabilities to Capital|Short-Term Debt to Equity Cellectis S.A.|CLLS - Company Debts|Debt to Book Capitalization Ratio Cellectis SA|CLLS - Company Long-Term Debt|Company Current Liabilities Cellectis S.A.|Quick Ratio cellectis.com
- financial results and valuation multiples details:
CLLS - Annual Net Income|Projected Future Earnings Cellectis S.A.|CLLS - Market Cap to Earnings|Future Price to Earnings Cellectis S.A.|CLLS - Growth-Adjusted P/E Ratio|EV/EBITDA Multiple Cellectis SA|CLLS - Profit before interest, taxes and amortization|Net earnings per share for the last 12 months Cellectis S.A.|CLLS - Earnings per share for the trailing year|Year-over-year net earnings per share growth for the last 12 months cellectis.com|CLLS - Net earnings per one share growth for the current year|Earnings growth forecast for next year Cellectis S.A.
General company analysis:CLLS Cellectis
Brand item of Cellectis S.A.

Cellectis S.A. (CLLS) is scaling its genome editing platform through strategic partnerships with pharmaceutical behemoths. An analysis of the company's forward P/E valuation on GURU.Markets allows for a comparison of the current share price against expected future earnings. This metric measures market optimism regarding the commercialization pace of allogeneic CAR-T therapies. This chart reflects the balance between growth potential and the risk of overvaluation. It is critical for investors to assess the trend regarding the asset's reliability.

Competing companies

Forward P/E Multiple LEGN|Sana Biotechnology Inc (SANA) - Forward Price to Earnings Multiple|Autolus Pharma - Projected Price to Earnings|Allogene Corp (ALLO) - Projected Price to Earnings Ratio|RNAC: Projected Price to Earnings|Future Price to Earnings Multiple CRBU (cariboubio.com)|TIL: Forward P/E Multiple|Projected Price to Earnings Genenta Science|IPSC (Century Tx) - Forward P/E Multiple|Projected Price to Earnings Ratio Jasper Bio JSPR|Future Price to Earnings Senti Biosciences, Inc. (SNTI)|Future Price to Earnings ADAP (adaptimmune.com)|Future Price to Earnings CERo Therapeutics Holdings CERO|Alaunos Therapeutics Inc. - Future Price to Earnings|ACHL: Projected Price to Earnings|Future Price to Earnings Multiple CRGX (CARGO Therapeutics, Inc)|PSTX: Forward P/E Multiple|Forward Price to Earnings Multiple 2seventybio.com TSVT|GRCL (Gracell Biotechnologies Inc.) - Forward P/E Multiple